<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Epileptol</journal-id><journal-id journal-id-type="iso-abbrev">Acta Epileptol</journal-id><journal-title-group><journal-title>Acta Epileptologica</journal-title></journal-title-group><issn pub-type="ppub">2096-9384</issn><issn pub-type="epub">2524-4434</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40405274</article-id><article-id pub-id-type="pmc">PMC12100867</article-id>
<article-id pub-id-type="publisher-id">213</article-id><article-id pub-id-type="doi">10.1186/s42494-025-00213-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Seizure frequency, APOE &#x003b5;4, and cognitive function in older people with epilepsy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yiling</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Zhenxu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Xiaowen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Saineng</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Luxin</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Qianhua</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Ding</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Jianhong</given-names></name><address><email>wang_jianhong@fudan.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhu</surname><given-names>Guoxing</given-names></name><address><email>zhuguoxing@huashan.org.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05201qm87</institution-id><institution-id institution-id-type="GRID">grid.411405.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 8861</institution-id><institution>Department of Neurology, </institution><institution>Huashan Hospital, Fudan University, </institution></institution-wrap>12 Wulumuqi Middle Road, Shanghai, 200040 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05201qm87</institution-id><institution-id institution-id-type="GRID">grid.411405.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 8861</institution-id><institution>National Clinical Research Center for Aging and Medicine, </institution><institution>Huashan Hospital, Fudan University, </institution></institution-wrap>12 Wulumuqi Middle Road, Shanghai, 200040 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05201qm87</institution-id><institution-id institution-id-type="GRID">grid.411405.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 8861</institution-id><institution>National Center for Neurological Disorders, </institution><institution>Huashan Hospital, Fudan University, </institution></institution-wrap>12 Wulumuqi Middle Road, Shanghai, 200040 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05201qm87</institution-id><institution-id institution-id-type="GRID">grid.411405.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 8861</institution-id><institution>Institute of Neurology, </institution><institution>Huashan Hospital, Fudan University, </institution></institution-wrap>12 Wulumuqi Middle Road, Shanghai, 200040 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05201qm87</institution-id><institution-id institution-id-type="GRID">grid.411405.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 8861</institution-id><institution>Department of Neurosurgery, </institution><institution>Huashan Hospital, Fudan University, </institution></institution-wrap>12 Wulumuqi Middle Road, Shanghai, 200040 China </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>7</volume><elocation-id>30</elocation-id><history><date date-type="received"><day>28</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>5</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Cognitive impairment represents a major comorbidity among older adults with epilepsy. This study aimed to explore the association between the apolipoprotein E&#x000a0;(<italic>APOE</italic>) &#x003b5;4 allele and cognitive function in older people with epilepsy.</p></sec><sec><title>Methods</title><p id="Par2">People with epilepsy aged&#x02009;&#x02265;&#x02009;50&#x000a0;years were enrolled at an outpatient clinic of epilepsy from November 2019 to July 2024. Blood samples were collected for APOE genotyping. Participants were categorized into two groups based on the presence of the <italic>APOE &#x003b5;4</italic> allele: <italic>APOE &#x003b5;4</italic>&#x000a0;(+/-). Cognitive function was assessed using a battery with neuropsychological tests. Based on Mini-Mental State Examination&#x000a0;(MMSE) scores, participants were defined as unimpaired cognition&#x000a0;(UC)&#x000a0;(MMSE&#x02009;&#x02265;&#x02009;27) and cognitive impairment&#x000a0;(CI)&#x000a0;(MMSE&#x02009;&#x0003c;&#x02009;27). Seizure frequency was categorized into low&#x000a0;(&#x02264;&#x02009;3/year) and high&#x000a0;(&#x0003e;&#x02009;3/year) groups. Multivariate logistic regression analysis and general linear models were employed to identify factors associated with cognitive function.</p></sec><sec><title>Results</title><p id="Par3">Among 110 participants, 51&#x000a0;(46.4%) were defined as CI. Compared with UC group, the CI group was older&#x000a0;(65.1&#x02009;&#x000b1;&#x02009;7.6 vs 60.8&#x02009;&#x000b1;&#x02009;6.8&#x000a0;years, <italic>P</italic>&#x02009;=&#x02009;0.002), with lower educational level&#x000a0;(9.0&#x000a0;[7.0,&#x000a0;11.0] vs 12.0&#x000a0;[9.0,&#x000a0;13.0] years, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), and higher seizure frequency (12.0 [1.0, 24.0] vs 1.0 [0.0, 12.0] times/year, <italic>P</italic>&#x02009;=&#x02009;0.005). High seizure frequency (OR&#x02009;=&#x02009;3.94, 95% CI [1.34, 11.61], <italic>P</italic>&#x02009;=&#x02009;0.013) and more <italic>APOE &#x003b5;4</italic> alleles&#x000a0;(OR&#x02009;=&#x02009;3.28, 95% CI [1.09, 9.83], <italic>P</italic>&#x02009;=&#x02009;0.034) were risk factors for CI. An interactive effect between the number of <italic>APOE &#x003b5;4</italic> alleles and seizure frequency was observed&#x000a0;(<italic>P</italic>&#x02009;=&#x02009;0.002). Compared to participants with <italic>APOE &#x003b5;4</italic>&#x000a0;(-) and low seizure frequency, those with <italic>APOE &#x003b5;4</italic>&#x000a0;(-) and high seizure frequency showed a threefold risk of CI&#x000a0;(OR&#x02009;=&#x02009;3.34,&#x000a0;95%&#x000a0;CI [0.99, 11.25], <italic>P</italic>&#x02009;=&#x02009;0.051), while those with <italic>APOE &#x003b5;4</italic>&#x000a0;(+) and high frequency demonstrated the highest risk of CI&#x000a0;(OR&#x02009;=&#x02009;10.53, 95%&#x000a0;CI [1.75, 63.47],&#x000a0;<italic>P</italic>&#x02009;=&#x02009;0.010).</p></sec><sec><title>Conclusions</title><p id="Par4">The synergistic effect of <italic>APOE &#x003b5;4</italic> allele and seizure frequency on cognitive function suggested their importance in clinical assessments and therapeutic approaches in managing older people with epilepsy.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Epilepsy</kwd><kwd><italic>APOE</italic></kwd><kwd>Older adults</kwd><kwd>Seizure frequency</kwd><kwd>Cognitive impairment</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; West China Hospital 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec2"><title>Background</title><p id="Par17">Epilepsy is one of the common neurological disorders, with a prevalence of approximately 6 per 1000 persons and an incidence of 68 per 100,000 person-years [<xref ref-type="bibr" rid="CR1">1</xref>]. The incidence of epilepsy increases steadily after 50 years of age, and is up to approximately twice that of younger adults [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par18">Epilepsy and its comorbidities pose a tremendous burden in older people with epilepsy and the society. Epilepsy is considered to have a potential bidirectional association with Alzheimer&#x02019;s disease&#x000a0;(AD), suggesting that the cognitive impairment in people with epilepsy may have similar pathological changes with AD [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. This notion implies a need for further research to elucidate the mechanisms underlying these conditions and to explore potential therapeutic targets that could address both cognitive decline and epilepsy.</p><p id="Par19">Apolipoprotein E&#x000a0;(<italic>APOE</italic>) gene, considered as a genetic factor of AD, is also associated with epilepsy. Compared with other genotypes, <italic>APOE &#x003b5;4/&#x003b5;4</italic> carriers have the smallest neurons, the&#x000a0;lowest acute phase responses, the&#x000a0;highest markers of stress, and lower level of intraneuronal APOE protein. This diminished APOE protein can promote aggregation of amyloid [<xref ref-type="bibr" rid="CR5">5</xref>], and further impair&#x000a0;neuronal repair and increase the seizure&#x000a0;susceptibility [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. The proportion of <italic>APOE &#x003b5;4</italic> allele is higher in people with epilepsy, especially those with temporal lobe epilepsy&#x000a0;(TLE), compared to normal people [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par20">As a clinical characteristic of epilepsy, seizure frequency has also been shown to increase the risk of cognitive impairment and dementia, especially in individuals with no prior cognitive problems or mild cognitive impairment [<xref ref-type="bibr" rid="CR9">9</xref>].&#x000a0;In this study, we intended to verify the hypothesis that cognitive function may be impacted by <italic>APOE &#x003b5;4</italic> allele and seizure frequency in older people with epilepsy.</p></sec><sec id="Sec3"><title>Methods</title><sec id="Sec4"><title>Study participants</title><p id="Par21">We enrolled older people with epilepsy from the outpatient epilepsy clinic at Huashan Hospital, Shanghai, between November&#x000a0;2019 and July&#x000a0;2024. Inclusion criteria were as follows: 1) age&#x02009;&#x02265;&#x02009;50 years; 2)&#x000a0;met the 2017&#x000a0;International League Against Epilepsy diagnostic criteria for epilepsy [<xref ref-type="bibr" rid="CR10">10</xref>]; and 3) agreed to participate in this study. Participants were excluded if they: 1) were diagnosed with severe brain trauma or cerebrovascular disease; 2) were diagnosed with a neurological disorder that could affect cognitive function, such as AD or Parkinson&#x02019;s disease [<xref ref-type="bibr" rid="CR11">11</xref>], or had a history of severe mental disorders. In the current study, we also excluded participants who:&#x000a0;1) had significant hearing or visual impairments that would preclude participation in cognitive assessments; 2) did not provide blood samples for <italic>APOE</italic> genotyping test. The procedure of recruitment is shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart of participants recruitment for the study. Abbreviation: APOE &#x003b5;4: Apolipoprotein E &#x003b5;4; MMSE: Mini-Mental Status Examination</p></caption><graphic xlink:href="42494_2025_213_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec5"><title>Demographic data and clinical characteristics</title><p id="Par22">Demographic data was collected through a questionnaire administered by trained health professionals during in-person visits, including age, gender, and education year.</p><p id="Par23">Clinical characteristics were collected through inquiry and questionnaire, including age at onset, disease duration, using ASMs or not, seizure frequency, and seizure type. The frequency of seizures in the previous year was retrospectively reviewed. Seizure freedom for more than one year was used as the criterion for well-controlled epilepsy. In this study, participants were categorized into two groups based on the median of seizure frequency in the previous one year: low seizure frequency&#x000a0;(&#x02264;&#x02009;3 seizures per year) and high seizure frequency&#x000a0;(&#x0003e;&#x02009;3 seizures per year).</p><p id="Par24">We collected detailed medical history of hypertension, diabetes, and dyslipidemia through a combination of medical record reviews and health questionnaires.</p></sec><sec id="Sec6"><title>APOE genotype assessment</title><p id="Par25">DNA was extracted from blood, and <italic>APOE</italic> genotyping was conducted by the TaqMan single-nucleotide polymorphism method [<xref ref-type="bibr" rid="CR12">12</xref>]. Participants with at least one <italic>APOE &#x003b5;4</italic> allele were categorized as <italic>APOE &#x003b5;4</italic>&#x000a0;(+), whereas those devoid of any <italic>APOE &#x003b5;4</italic> allele were classified as <italic>APOE &#x003b5;4</italic>&#x000a0;(-).</p></sec><sec id="Sec7"><title>Neuropsychological testing</title><p id="Par26">Cognitive function was assessed using the Huashan version battery of the neuropsychological tests, which has been validated through rigorous reliability and validity testing in Chinese population [<xref ref-type="bibr" rid="CR13">13</xref>].<list list-type="simple"><list-item><label>a</label><p id="Par27">The Chinese version of the Mini-Mental Status Examination&#x000a0;(MMSE) was used to assess global cognitive function [<xref ref-type="bibr" rid="CR14">14</xref>]. Participants were further divided into two groups according to the median score of MMSE: unimpaired cognition&#x000a0;(UC)&#x000a0;(MMSE score&#x02009;&#x02265;&#x02009;27) and cognitive impairment&#x000a0;(CI)&#x000a0;(MMSE score&#x02009;&#x0003c;&#x02009;27).</p></list-item><list-item><label>b</label><p id="Par28">The Auditory Verbal Learning Test&#x000a0;(AVLT) or Huashan Object Memory Test&#x000a0;(HOMT) was used to measure verbal memory. For participants with&#x02009;&#x0003c;&#x02009;6 years of education, the HOMT was administered, whereas for those with&#x02009;&#x02265;&#x02009;6 years of education, the AVLT was chosen for assessment. Participants were asked to recall 12 words over 5 trials. We used the results of the 5th trial as the long-term delayed recall to represent the memory function [<xref ref-type="bibr" rid="CR15">15</xref>].</p></list-item><list-item><label>c</label><p id="Par29">Trail Making Tests A&#x000a0;(TMT-A) and B&#x000a0;(TMT-B) were adopted to evaluate the attention and executive function, respectively [<xref ref-type="bibr" rid="CR13">13</xref>].The test consists of two parts: TMT-A, participants needed to connect all numbers in sequential order; TMT-B, participants were asked to connect numbers in sequential order with the alternation of square and circle&#x000a0;(e.g., &#x0201c;1&#x0201d; in a square, &#x0201c;2&#x0201d; in a circle).&#x000a0;The completion time&#x000a0;(seconds) was recorded and transformed to speed&#x000a0;(1/time).</p></list-item><list-item><label>d</label><p id="Par30">The Stick Test was used to evaluate the visuospatial function [<xref ref-type="bibr" rid="CR13">13</xref>]. Participants were asked to copy the examiner&#x02019;s model exactly with four wooden sticks. After that, participants were asked to construct the reverse pattern of the model.</p></list-item><list-item><label>e</label><p id="Par31">The Modified Common Objects Sorting Test&#x000a0;(COST) was used to assess the language function [<xref ref-type="bibr" rid="CR13">13</xref>].&#x000a0;Participants were asked to sort all 42 objects into 7 different groups, and provided the reason for the sorting.</p><p id="Par32">Scores of each domain-specific test were standardized to <italic>z</italic> scores by subtracting the mean and dividing by the standard deviation&#x000a0;(SD).</p></list-item></list></p></sec><sec id="Sec8"><title>Statistical analysis</title><p id="Par33">Normally distributed continuous data are presented as Mean&#x02009;&#x000b1;&#x02009;SD, while skewed distribution continuous data are expressed as Median&#x000a0;(IQR). Categorical variables are represented as <italic>n</italic>&#x000a0;(%). Significance analysis for continuous data was conducted using student <italic>t</italic>-test or Mann-Whtiney U-test, and Pearson chi-square test was applied for analysis of categorical variables. Multivariate logistic regression model adjusted for confounders&#x000a0;(age, sex, years of education, epilepsy duration, hypertension, diabetes, and dyslipidemia) was used to test the association between seizure frequency, APOE&#x000a0;&#x003b5;4, and cognitive function. General Linear Model was used to explore the synergistic effects of seizure frequency and APOE&#x000a0;&#x003b5;4 on cognitive function, adjusting for age, gender, years of education, disease duration, seizure type, hypertension, diabetes, and dyslipidemia. To evaluate the combined effect of APOE &#x003b5;4 status and seizure frequency on cognitive impairment, we constructed a categorical variable &#x0201c;Group&#x0201d;, with four levels (<italic>APOE &#x003b5;4</italic>&#x000a0;[-] and low seizure frequency, <italic>APOE &#x003b5;4</italic>&#x000a0;[-] and high seizure frequency, <italic>APOE &#x003b5;4</italic>&#x000a0;[+] and low seizure frequency, and <italic>APOE &#x003b5;4</italic>&#x000a0;[+] and high seizure frequency) based on the interaction between these factors. This &#x0201c;Group&#x0201d; variable was then incorporated as a factor in a univariable and a multivariate logistic regression models adjusted for age, gender, educational level, duration of epilepsy, seizure type, hypertension, diabetes, and dyslipidemia, and estimate odds ratios&#x000a0;(OR) for cognitive impairment across the other levels of the &#x0201c;Group&#x0201d; variable relative to the reference group with &#x0201c;<italic>APOE &#x003b5;4</italic>&#x000a0;(-) and low seizure frequency&#x0201d;.</p><p id="Par34">SPSS 26.0 was used for data analysis. Two-sided <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Characteristics of study participants</title><p id="Par35">This study included 110 older people with epilepsy&#x000a0;(55 males, 55 females). The age of all participants ranged from 50 to 81 years&#x000a0;(mean 62.8&#x02009;&#x000b1;&#x02009;7.5 years).&#x000a0;The median duration of epilepsy was 12.5 years&#x000a0;(IQR 5.0,&#x000a0;32.0), with a median age at onset of 48.5 years&#x000a0;(IQR&#x000a0;30.8,&#x000a0;61.0). The majority of participants&#x000a0;(96.4%) had focal seizures, and the rest had generalized seizures. Six participants&#x000a0;(5.5%) discontinued anti-seizure medication&#x000a0;(ASM) during the course of the disease. Thirty-three participants&#x000a0;(30.0%) were seizure-free for one year, whereas 56&#x000a0;participants&#x000a0;(50.9%) had four or more seizures per year. There were 20 participants&#x000a0;(18.2%) with one <italic>APOE &#x003b5;4</italic> allele and 3 participants&#x000a0;(2.7%) with <italic>APOE &#x003b5;4/&#x003b5;4</italic>. In terms of comorbidities, 30 participants&#x000a0;(27.3%) had a history of hypertension, 7&#x000a0;(6.4%) had diabetes, and 38&#x000a0;(34.5%) had dyslipidemia. The median MMSE score was 27.0&#x000a0;(IQR 25.0,&#x000a0;28.0).</p><p id="Par36">As shown in Table <xref rid="Tab1" ref-type="table">1</xref>, compared with the UC group, CI participants were older&#x000a0;(65.1&#x02009;&#x000b1;&#x02009;7.6 vs 60.8&#x02009;&#x000b1;&#x02009;6.8 years, <italic>P</italic>&#x02009;=&#x02009;0.002), had a lower level of education&#x000a0;(9.0&#x000a0;[7.0,&#x000a0;11.0] vs 12.0&#x000a0;[9.0,&#x000a0;13.0] years, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), and had a higher seizure frequency&#x000a0;(12.0&#x000a0;[1.0,&#x000a0;24.0] times/year vs 1.0&#x000a0;[0.0,&#x000a0;12.0] times/year, <italic>P</italic>&#x02009;=&#x02009;0.005). The differences between the two groups in cognitive domains are mainly shown in global cognition&#x000a0;(24.0&#x000a0;[21.0,&#x000a0;26.0] vs&#x000a0;28.0&#x000a0;[28.0,&#x000a0;29.0],&#x000a0;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), memory&#x000a0;(-0.4&#x000a0;[-1.3,&#x000a0;0.1]&#x000a0;vs 0.4&#x000a0;[-0.4,&#x000a0;1.3],&#x000a0;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), attention&#x000a0;(-0.6&#x000a0;[-1.1,&#x000a0;-0.1] vs&#x000a0;0.4&#x000a0;[-0.3,&#x000a0;1.2],&#x000a0;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), executive function&#x000a0;(-0.5&#x000a0;[-0.4,&#x000a0;0.9],&#x000a0;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), visuospatial function (-0.4&#x000a0;[-0.7,&#x000a0;0.4] vs&#x000a0;0.34&#x000a0;[0.0,&#x000a0;1.0],&#x000a0;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), and language&#x000a0;(-0.1&#x000a0;[-0.5,&#x000a0;0.4]&#x000a0;vs 0.4&#x000a0;[0.1,&#x000a0;0.6],&#x000a0;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of the participants of unimpaired cognitive function and impaired cognitive function</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Unimpaired cognitive function&#x000a0;(<italic>n</italic>&#x02009;=&#x02009;59)</th><th align="left">Impaired cognitive function&#x000a0;(<italic>n</italic>&#x02009;=&#x02009;51)</th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">Demographic&#x000a0;information</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Age,&#x000a0;years, M&#x02009;&#x000b1;&#x02009;SD</td><td align="left">60.8&#x02009;&#x000b1;&#x02009;6.8</td><td align="left">65.1&#x02009;&#x000b1;&#x02009;7.6</td><td char="." align="char">0.002</td></tr><tr><td align="left">Gender</td><td align="left"/><td align="left"/><td char="." align="char">0.566</td></tr><tr><td align="left">&#x02003;Men, <italic>n</italic>(%)</td><td align="left">28&#x000a0;(47.5)</td><td align="left">27&#x000a0;(52.9)</td><td char="." align="char"/></tr><tr><td align="left">&#x02003;Women, <italic>n</italic>(%)</td><td align="left">31&#x000a0;(52.5)</td><td align="left">24&#x000a0;(47.1)</td><td char="." align="char"/></tr><tr><td align="left">Education,&#x000a0;years,&#x000a0;median&#x000a0;(IQR)</td><td align="left">12.0&#x000a0;(9.0,&#x000a0;13.0)</td><td align="left">9.0&#x000a0;(7.0,&#x000a0;11.0)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" colspan="4">Clinical information</td></tr><tr><td align="left">&#x02003;Age at onset,&#x000a0;years,&#x000a0;median&#x000a0;(IQR)</td><td align="left">48.0&#x000a0;(29.0,&#x000a0;59.0)</td><td align="left">49.0&#x000a0;(31.0,&#x000a0;65.0)</td><td char="." align="char">0.417</td></tr><tr><td align="left">&#x02003;Duration,&#x000a0;years,&#x000a0;median&#x000a0;(IQR)</td><td align="left">11.0&#x000a0;(5.0,&#x000a0;30.0)</td><td align="left">14.0&#x000a0;(5.0,&#x000a0;33.0)</td><td char="." align="char">0.688</td></tr><tr><td align="left">&#x02003;Using ASMs, <italic>n</italic>&#x000a0;(%)</td><td align="left">56&#x000a0;(94.9)</td><td align="left">48&#x000a0;(94.1)</td><td char="." align="char">&#x02009;&#x0003e;&#x02009;0.999</td></tr><tr><td align="left">&#x02003;Seizure&#x000a0;frequency,&#x000a0;times/year, median&#x000a0;(IQR)</td><td align="left">1.0&#x000a0;(0.0,&#x000a0;12.0)</td><td align="left">12.0&#x000a0;(1.0,&#x000a0;24.0)</td><td char="." align="char">0.005</td></tr><tr><td align="left">Seizure type</td><td align="left"/><td align="left"/><td char="." align="char">0.717</td></tr><tr><td align="left">&#x02003;Focal onset,&#x000a0;<italic>n</italic>&#x000a0;(%)</td><td align="left">56&#x000a0;(94.9)</td><td align="left">50&#x000a0;(98.0)</td><td char="." align="char"/></tr><tr><td align="left">&#x02003;Generalized onset, <italic>n</italic>&#x000a0;(%)</td><td align="left">3&#x000a0;(5.1)</td><td align="left">1&#x000a0;(2.0)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">Clinical health parameter</td></tr><tr><td align="left">&#x02003;Hypertension, <italic>n</italic>&#x000a0;(%)</td><td align="left">14&#x000a0;(23.7)</td><td align="left">16&#x000a0;(31.4)</td><td char="." align="char">0.369</td></tr><tr><td align="left">&#x02003;Diabetes, <italic>n</italic>&#x000a0;(%)</td><td align="left">3&#x000a0;(5.7)</td><td align="left">4&#x000a0;(8.9)</td><td char="." align="char">0.822</td></tr><tr><td align="left">&#x02003;Dyslipidemia,&#x000a0;<italic>n</italic>&#x000a0;(%)</td><td align="left">25&#x000a0;(42.4)</td><td align="left">13&#x000a0;(25.5)</td><td char="." align="char">0.063</td></tr><tr><td align="left" colspan="4"><italic>APOE</italic> genotype</td></tr><tr><td align="left">&#x02003;Number of <italic>APOE &#x003b5;4</italic></td><td align="left"/><td align="left"/><td char="." align="char">0.057</td></tr><tr><td align="left">&#x02003;0, <italic>n</italic>&#x000a0;(%)</td><td align="left">50&#x000a0;(84.7)</td><td align="left">37&#x000a0;(72.5)</td><td char="." align="char"/></tr><tr><td align="left">&#x02003;1, <italic>n</italic>&#x000a0;(%)</td><td align="left">9&#x000a0;(15.3)</td><td align="left">11&#x000a0;(21.6)</td><td char="." align="char"/></tr><tr><td align="left">&#x02003;2, <italic>n</italic>&#x000a0;(%)</td><td align="left">0&#x000a0;(0.0)</td><td align="left">3&#x000a0;(5.9)</td><td char="." align="char"/></tr><tr><td align="left"><italic>APOE &#x003b5;4</italic> allele</td><td align="left"/><td align="left"/><td char="." align="char">0.117</td></tr><tr><td align="left">APOE &#x003b5;4&#x000a0;(-), <italic>n</italic>&#x000a0;(%)</td><td align="left">50&#x000a0;(84.7)</td><td align="left">37&#x000a0;(72.5)</td><td char="." align="char"/></tr><tr><td align="left">APOE &#x003b5;4&#x000a0;(+), <italic>n</italic>&#x000a0;(%)</td><td align="left">9&#x000a0;(15.3)</td><td align="left">14&#x000a0;(27.5)</td><td char="." align="char"/></tr><tr><td align="left">MMSE, median&#x000a0;(IQR)</td><td align="left">28.0&#x000a0;(28.0,&#x000a0;29.0)</td><td align="left">24.0&#x000a0;(21.0,&#x000a0;26.0)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" colspan="4">Domain-specific cognition<sup>a</sup></td></tr><tr><td align="left">&#x02003;Memory, median&#x000a0;(IQR)</td><td align="left">0.4&#x000a0;(-0.4,&#x000a0;1.3)</td><td align="left">-0.4&#x000a0;(-1.3,&#x000a0;0.1)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Attention, median&#x000a0;(IQR)</td><td align="left">0.4&#x000a0;(-0.3,&#x000a0;1.2)</td><td align="left">-0.6&#x000a0;(-1.1,&#x000a0;-0.1)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Executive function, median&#x000a0;(IQR)</td><td align="left">0.2&#x000a0;(-0.4,&#x000a0;0.9)</td><td align="left">-0.5&#x000a0;(-1.2,&#x000a0;-0.0)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Visuospatial function, median&#x000a0;(IQR)</td><td align="left">0.3 (0.0,1.0)</td><td align="left">-0.4&#x000a0;(-0.7,&#x000a0;0.4)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Language, median&#x000a0;(IQR)</td><td align="left">0.4&#x000a0;(0.1,&#x000a0;0.6)</td><td align="left">-0.1&#x000a0;(-0.5,&#x000a0;0.4)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations</italic>: <italic>M</italic> Mean, <italic>SD</italic> Standard division, <italic>IQR</italic> Interquartile range, <italic>ASM</italic> Antiseizure medication, <italic>APOE</italic> &#x003b5;4, Apolipoprotein E &#x003b5;4, <italic>MMSE</italic> Mini-Mental Status Examination</p><p><sup>a</sup>Domain specific tests were standardized to <italic>z</italic> scores</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Association between seizure frequency, APOE&#x003b5;4 and cognitive function</title><p id="Par37">After adjusting for age, gender, years of education, disease duration, seizure type, hypertension, diabetes, and dyslipidemia, high seizure frequency&#x000a0;(OR&#x02009;=&#x02009;3.94, 95% CI [1.34, 11.61], <italic>P</italic>&#x02009;=&#x02009;0.013) and the number of <italic>APOE &#x003b5;4</italic> alleles&#x000a0;(OR&#x02009;=&#x02009;3.28, 95% CI [1.09, 9.83], <italic>P</italic>&#x02009;=&#x02009;0.034) were found to be associated with CI, respectively.</p></sec><sec id="Sec12"><title>Additive effect of seizure frequency and <italic>APOE &#x003b5;4</italic> on cognitive function</title><p id="Par38">The General Linear Model showed an interaction between seizure frequency and the number of <italic>APOE &#x003b5;4</italic> alleles&#x000a0;(F&#x02009;=&#x02009;6.709, <italic>P</italic>&#x02009;=&#x02009;0.002) on MMSE score.</p><p id="Par39">As shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>, based on seizure frequency and <italic>APOE &#x003b5;4</italic> carrier status, we stratified participants to four distinct groups: <italic>APOE &#x003b5;4&#x000a0;</italic>(-) and low frequency&#x000a0;(<italic>N</italic>&#x02009;=&#x02009;44), <italic>APOE &#x003b5;4</italic>&#x000a0;(-) and high frequency&#x000a0;(<italic>N</italic>&#x02009;=&#x02009;43), <italic>APOE &#x003b5;4</italic>&#x000a0;(+) and low frequency&#x000a0;(<italic>N</italic>&#x02009;=&#x02009;10), and <italic>APOE &#x003b5;4</italic>&#x000a0;(+) and high frequency&#x000a0;(<italic>N</italic>&#x02009;=&#x02009;13).</p><p id="Par40">Compared to participants with <italic>APOE &#x003b5;4</italic>&#x000a0;(-) and low seizure frequency, those with <italic>APOE &#x003b5;4</italic>&#x000a0;(-) and high seizure frequency had an increased risk of CI&#x000a0;(OR&#x02009;=&#x02009;3.01, 95%CI 1.24,&#x000a0;7.29, <italic>P</italic>&#x02009;=&#x02009;0.015). Participants with <italic>APOE &#x003b5;4&#x000a0;</italic>(+) and high seizure frequency had an even higher risk of CI&#x000a0;(OR&#x02009;=&#x02009;7.95, 95% CI [1.88, 33.67], <italic>P</italic>&#x02009;=&#x02009;0.005).&#x000a0;After adjusting for age, gender, educational level, duration of epilepsy, seizure type, hypertension, diabetes, and dyslipidemia, those with <italic>APOE &#x003b5;4</italic>&#x000a0;(-) and high seizure frequency showed a threefold risk of CI&#x000a0;(OR&#x02009;=&#x02009;3.34,&#x000a0;95%&#x000a0;CI [0.99, 11.25], <italic>P</italic>&#x02009;=&#x02009;0.051), while those with <italic>APOE &#x003b5;4</italic>&#x000a0;(+) and high frequency demonstrated the highest risk of CI&#x000a0;(OR&#x02009;=&#x02009;10.53, 95%&#x000a0;CI [1.75, 63.47],&#x000a0;<italic>P</italic>&#x02009;=&#x02009;0.010)&#x000a0;(Fig. <xref rid="Fig2" ref-type="fig">2</xref> and Table <xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Interaction between <italic>APOE &#x003b5;4</italic> allele status and seizure frequency in risk of cognitive impairment. Abbreviations: <italic>APOE</italic>&#x000a0;<italic>&#x003b5;4</italic>, apolipoprotein E allele 4. a: The multivariate analysis adjusted potential confounders, specifically: age, gender, educational level, duration of epilepsy, seizure type, hypertension, diabetes, and dyslipidemia</p></caption><graphic xlink:href="42494_2025_213_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Multivariate analysis of cognitive function in older people with epilepsy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">&#x003b2;</th><th align="left">SE</th><th align="left"><italic>P</italic>-value</th><th align="left">OR&#x000a0;(95%CI)</th></tr></thead><tbody><tr><td align="left">Age</td><td char="." align="char">0.12</td><td char="." align="char">0.05</td><td char="." align="char">0.007</td><td align="left">1.13&#x000a0;(1.03,&#x000a0;1.23)</td></tr><tr><td align="left">Male</td><td char="." align="char">0.30</td><td char="." align="char">0.54</td><td char="." align="char">0.581</td><td align="left">1.35&#x000a0;(0.46,&#x000a0;3.93)</td></tr><tr><td align="left">Education year</td><td char="." align="char">-0.39</td><td char="." align="char">0.11</td><td char="." align="char">0.000</td><td align="left">0.68&#x000a0;(0.55,&#x000a0;0.84)</td></tr><tr><td align="left">Duration of epilepsy</td><td char="." align="char">0.01</td><td char="." align="char">0.02</td><td char="." align="char">0.687</td><td align="left">1.01&#x000a0;(0.97,&#x000a0;1.04)</td></tr><tr><td align="left">Seizure type</td><td char="." align="char">0.65</td><td char="." align="char">1.74</td><td char="." align="char">0.709</td><td align="left">1.92&#x000a0;(0.06,&#x000a0;58.37)</td></tr><tr><td align="left">Hypertension</td><td char="." align="char">0.79</td><td char="." align="char">0.68</td><td char="." align="char">0.246</td><td align="left">2.21&#x000a0;(0.58,&#x000a0;8.45)</td></tr><tr><td align="left">Diabetes</td><td char="." align="char">0.63</td><td char="." align="char">1.22</td><td char="." align="char">0.607</td><td align="left">1.87&#x000a0;(0.17,&#x000a0;20.25)</td></tr><tr><td align="left">Dyslipidemia</td><td char="." align="char">-0.58</td><td char="." align="char">0.58</td><td char="." align="char">0.316</td><td align="left">0.56&#x000a0;(0.18,&#x000a0;1.74)</td></tr><tr><td align="left">APOE&#x003b5;4&#x000a0;(-) and low seizure frequency</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char">Ref</td><td align="left"/></tr><tr><td align="left">APOE&#x003b5;4&#x000a0;(+) and low seizure frequency</td><td char="." align="char">0.77</td><td char="." align="char">0.96</td><td char="." align="char">0.421</td><td align="left">2.17&#x000a0;(0.33,&#x000a0;14.20)</td></tr><tr><td align="left">APOE&#x003b5;4&#x000a0;(-) and high seizure frequency</td><td char="." align="char">1.21</td><td char="." align="char">0.62</td><td char="." align="char">0.051</td><td align="left">3.34&#x000a0;(0.99,&#x000a0;11.25)</td></tr><tr><td align="left">APOE&#x003b5;4&#x000a0;(+) and high seizure frequency</td><td char="." align="char">2.36</td><td char="." align="char">0.92</td><td char="." align="char">0.010</td><td align="left">10.53&#x000a0;(1.75,&#x000a0;63.47)</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations</italic>: <italic>APOE&#x000a0;&#x003b5;4</italic> Apolipoprotein E allele 4</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par41">In this study, we found CI participants were older, had a lower level of education, and had a higher seizure frequency than UC group. Notably, poorer cognitive performance was observed in global cognition and each specific cognitive domain. In addition, high seizure frequency and more <italic>APOE &#x003b5;4</italic> allele were identified as risk factors associated with cognitive function. Specifically, participants with <italic>APOE &#x003b5;4</italic>&#x000a0;(+) and high seizure frequency had the highest risk of CI, which means that the <italic>APOE &#x003b5;4</italic> status may act synergistically with high seizure frequency to exacerbate cognitive decline in older adults with epilepsy.</p><p id="Par42">Our study was consistent with some previous studies. Sekimoto et al. found a significant negative correlation&#x000a0;(<italic>&#x003c1;</italic>&#x02009;=&#x02009;-0.46,&#x000a0;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01) between recent seizure frequency and delayed recall scores in people with late-onset TLE [<xref ref-type="bibr" rid="CR16">16</xref>]. Rawle et al. used a birth cohort analysis and found that the cumulative detrimental impact of <italic>APOE &#x003b5;4</italic> on memory from midlife to early old age displays dose-dependent effects&#x000a0;(&#x003b2;&#x02009;=&#x02009;-0.68 for heterozygotes vs &#x003b2;&#x02009;=&#x02009;-1.38 for homozygotes) [<xref ref-type="bibr" rid="CR17">17</xref>].&#x000a0;Gambardella et al. conducted a neuropsychological and molecular study in 138 patients with mild non-lesional TLE who rarely or never had seizures during follow-up and found that <italic>APOE</italic>&#x000a0;<italic>&#x003b5;4</italic> was associated with memory impairment&#x000a0;(OR 4.18,&#x000a0;95%&#x000a0;CI [1.66, 10.55]).&#x000a0;Furthermore, the interaction was found between disease duration and <italic>APOE &#x003b5;4</italic>. In individuals carrying <italic>APOE &#x003b5;4</italic> allele, the notable risk of CI reached&#x000a0;32.29&#x000a0;(OR 32.29,&#x000a0;95%&#x000a0;CI [5.23, 195.72])&#x000a0;when the disease duration longer than 25.5 years [<xref ref-type="bibr" rid="CR18">18</xref>].&#x000a0;A longitudinal study showed that older epilepsy patients with <italic>APOE &#x003b5;4</italic> allele were associated with 1.51&#x000a0;(95%&#x000a0;CI [-2.26, -0.75],&#x000a0;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) points faster cognitive decline than expected if epilepsy and <italic>APOE</italic>&#x000a0;<italic>&#x003b5;4</italic> acted independently [<xref ref-type="bibr" rid="CR19">19</xref>]. However, Doherty et al. compared the executive function of TLE with healthy people and found that APOE &#x003b5;4 status alone was not a significant predictor of executive function in TLE patients [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par43">These studies highlight the multi-factorial nature of CI in epilepsy, implicating both genetic predisposition via the <italic>APOE &#x003b5;4</italic> allele and clinical characteristics such as seizure frequency and epilepsy duration as critical contributors to cognition. Due to limitations such as cohort size, previous studies have primarily focused on cognitive profiles between individuals with epilepsy and healthy controls [<xref ref-type="bibr" rid="CR21">21</xref>]rather than exploring the unique impacts of epilepsy-related factors on cognition. To effectively identify cognitive impairment at its earliest stages within the epilepsy population, greater attention should be given to the distinctive effects of epilepsy itself on cognitive function. Moreover, many studies tended to describe clinical characteristics of epilepsy separately, neglecting examining interactions among multiple variables. Our study, however, conducted detailed comparison of epilepsy characteristics, comprehensive evaluation of cognitive function, and multivariate statistical models adjusting for potential confounders. Furthermore, we demonstrated the synergistic effect of <italic>APOE &#x003b5;4</italic> allele and seizure frequency on cognitive function in older people with epilepsy.</p><p id="Par44">The relationship between the <italic>APOE</italic>&#x000a0;<italic>&#x003b5;4</italic> allele and seizure frequency is based on a myriad of complex mechanisms, encompassing neuronal function, A&#x003b2; peptide generation, and the pathophysiology of epilepsy [<xref ref-type="bibr" rid="CR5">5</xref>]. Aboud et al. used superior temporal lobes of 92 participants and found smaller neurons and more markers of stress in <italic>APOE &#x003b5;4/&#x003b5;4</italic> group. These influences may contribute to the increase in frequency and intensity of seizures [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].&#x000a0;Seizure activity may sustain the dysfunction of regional neurovascular unit&#x000a0;(NVU), which orchestrates the coupling of neural activity with cerebral blood flow and regulates the integrity of the blood&#x02013;brain barrier&#x000a0;(BBB) to safeguard the structural and functional coherence of the central nervous system [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].&#x000a0;Disruption of NVU integrity leads to alterations in BBB structure or permeability, culminating in dysfunctions that have been implicated in cognitive impairment [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. Concurrently, with advancing age, the decline in neuronal plasticity impedes the ability to compensate the underlying pathological disruptions engendered by seizures, accelerating cerebral aging and cognitive decline [<xref ref-type="bibr" rid="CR24">24</xref>]. The cumulative effects of recurrent seizures, coupled with interictal epileptiform discharges, exacerbate cognitive deterioration [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par45">There were several limitations in this study. First, this study was designed as a cross-sectional study and cannot prove a causal relationship between APOE and seizure frequency synergies and cognitive impairment in older people with epilepsy. The number of patients included in this study mainly depended on outpatient visits, and strict sample size calculation was not carried out. It is necessary to further expand the sample size of the study to enhance the statistical power. Second, the seizure frequency in the past year may not well-represent the long-term situation. Third, previous studies have shown that ASMs may impact cognitive function of people with epilepsy [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. In our study, about 95% of participants were on ASM treatment. However, the specific ASM types and dosages could not be accurately recalled by the older people with epilepsy. Therefore we could not analysis the impact of ASMs on cognitive function. Forth, the lack of neuroimaging restricts our capacity to comprehensively assess the impact of structural abnormalities and vascular factors on the pathophysiology of epilepsy and cognitive decline. Fifth, defining high seizure frequency as&#x02009;&#x0003e;&#x02009;3 seizures/year was overly broad and fails to account for the variability within this spectrum. However, due to our limited sample size, we only could make two categories. Future studies should use more granular subgroup definitions such as&#x02009;&#x0003c;&#x02009;2 seizures/year, 3&#x02013;4 seizures/year, 1 seizure/month, and&#x02009;&#x0003e;&#x02009;1 seizure/month. Sixth, overall the sample size of <italic>APOE &#x003b5;4</italic> carriers was small, and the <italic>APOE &#x003b5;4/&#x003b5;4</italic> genotype was limited to three participants. Such small sample size adversely impacts the conclusion of the impact of <italic>APOE &#x003b5;4</italic> carriers on the neurocognitive assessment. Seventh, due to the limited sample size, our logistic regression analysis using a single categorical variable (four groups with <italic>APOE &#x003b5;4</italic> and seizure frequency combination) on cognitive impairment may reduce the statistical power of our findings. Future studies with larger cohorts are warranted to confirm these results and, if appropriate, to explore pairwise inter-group comparisons using multiple comparison corrections such as False Discovery Rate (FDR) or Bonferroni, while accounting for relevant confounders. Longitudinal cohorts with larger sample size may reduce bias and enhance statistics power.</p></sec><sec id="Sec14"><title>Conclusions</title><p id="Par46">Our study demonstrated the synergistic effect of <italic>APOE &#x003b5;4</italic> allele and high seizure frequency on worse cognitive function in older people with epilepsy. Our findings may help clinicians to identify individuals with high risk of cognitive impairment and adjust the therapeutic approaches in managing older people with epilepsy.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ASM</term><def><p id="Par5">Antiseizure medication</p></def></def-item><def-item><term>AD</term><def><p id="Par6">Alzheimer&#x02019;s disease</p></def></def-item><def-item><term>PD</term><def><p id="Par7">Parkinson&#x02019;s disease</p></def></def-item><def-item><term>APOE &#x003b5;4</term><def><p id="Par8">Apolipoprotein E &#x003b5;4</p></def></def-item><def-item><term>MMSE</term><def><p id="Par9">Mini-Mental Status Examination</p></def></def-item><def-item><term>UC</term><def><p id="Par10">Unimpaired cognition</p></def></def-item><def-item><term>CI</term><def><p id="Par11">Cognitive impairment</p></def></def-item><def-item><term>M</term><def><p id="Par12">Mean</p></def></def-item><def-item><term>SD</term><def><p id="Par13">Standard deviation</p></def></def-item><def-item><term>IQR</term><def><p id="Par14">Interquartile range</p></def></def-item><def-item><term>NVU</term><def><p id="Par15">Neurovascular unit</p></def></def-item><def-item><term>BBB</term><def><p id="Par16">Blood&#x02013;brain barrier</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>The authors thank Bingwen Bian, Fang Pei, Yan Zhang, Zhuqing Xue, Weiqing Xue, Xiuqin Wu, and Yuan Ni for their work of coordination and cognitive evaluation.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>DD, JW, and GZ supervised the research and manuscript revision. YC, ZX, XZ, LJ, SD and JW collected clinical data and blood samples from all participants. YC conducted the statistics analysis and wrote the draft of the manuscript. QZ evaluated the cognitive function. All authors contributed to the review and revision of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was sponsored by the coordinating project of neurology department of Huashan Hospital&#x000a0;[3030512199], the National Natural Science Foundation of China [82071456], Shanghai Academic Research Leader Program [21XD1420900], and Shanghai Municipal Commission of Health Program [20224Z0002].</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par47">This study was approved by the Institutional Review Board of Huashan Hospital&#x000a0;(No.&#x000a0;2020-065). Written informed consents were obtained from all participants or legal guardians.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par48">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par49">Author Ding Ding&#x000a0;is the member of the Editorial Board for <italic>Acta Epileptologica</italic>, who was not involved in the journal&#x02019;s review of or decisions related to this manuscript.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Devinsky</surname><given-names>O</given-names></name><name><surname>Vezzani</surname><given-names>A</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>TJ</given-names></name><name><surname>Jette</surname><given-names>N</given-names></name><name><surname>Scheffer</surname><given-names>IE</given-names></name><name><surname>De Curtis</surname><given-names>M</given-names></name><name><surname>Perucca</surname><given-names>P</given-names></name></person-group><article-title>Epilepsy</article-title><source>Nat Rev Dis Primers</source><year>2018</year><volume>4</volume><issue>1</issue><fpage>18024</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2018.24</pub-id><pub-id pub-id-type="pmid">29722352</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Devinsky O, Vezzani A, O&#x02019;Brien TJ, Jette N, Scheffer IE, De Curtis M, et al. Epilepsy. Nat Rev Dis Primers. 2018;4(1):18024.<pub-id pub-id-type="pmid">29722352</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>R</given-names></name></person-group><article-title>Epilepsy in elderly population: a comprehensive review</article-title><source>EC Neurol</source><year>2020</year><volume>12</volume><issue>6</issue><fpage>61</fpage><lpage>71</lpage></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Dutta R. Epilepsy in elderly population: a comprehensive review. EC Neurol. 2020;12(6):61&#x02013;71.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Beghi</surname><given-names>E</given-names></name><name><surname>Giussani</surname><given-names>G</given-names></name><name><surname>Costa</surname><given-names>C</given-names></name><name><surname>DiFrancesco</surname><given-names>JC</given-names></name><name><surname>Dhakar</surname><given-names>M</given-names></name><name><surname>Leppik</surname><given-names>I</given-names></name><etal/></person-group><article-title>The epidemiology of epilepsy in older adults: a narrative review by the ILAE Task Force on Epilepsy in the Elderly</article-title><source>Epilepsia</source><year>2023</year><volume>64</volume><issue>3</issue><fpage>586</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1111/epi.17494</pub-id><pub-id pub-id-type="pmid">36625133</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Beghi E, Giussani G, Costa C, DiFrancesco JC, Dhakar M, Leppik I, et al. The epidemiology of epilepsy in older adults: a narrative review by the ILAE Task Force on Epilepsy in the Elderly. Epilepsia. 2023;64(3):586&#x02013;601.<pub-id pub-id-type="pmid">36625133</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>A</given-names></name><name><surname>Jette</surname><given-names>N</given-names></name><name><surname>Husain</surname><given-names>M</given-names></name><name><surname>Sander</surname><given-names>JW</given-names></name></person-group><article-title>Epilepsy in older people</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10225</issue><fpage>735</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)33064-8</pub-id><pub-id pub-id-type="pmid">32113502</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Sen A, Jette N, Husain M, Sander JW. Epilepsy in older people. Lancet. 2020;395(10225):735&#x02013;48.<pub-id pub-id-type="pmid">32113502</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Aboud</surname><given-names>O</given-names></name><name><surname>Mrak</surname><given-names>RE</given-names></name><name><surname>Boop</surname><given-names>FA</given-names></name><name><surname>Griffin</surname><given-names>WST</given-names></name></person-group><article-title>Epilepsy: neuroinflammation, neurodegeneration, and APOE genotype</article-title><source>Acta Neuropathol Commun</source><year>2013</year><volume>1</volume><issue>1</issue><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/2051-5960-1-41</pub-id><pub-id pub-id-type="pmid">24252240</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Aboud O, Mrak RE, Boop FA, Griffin WST. Epilepsy: neuroinflammation, neurodegeneration, and APOE genotype. Acta Neuropathol Commun. 2013;1(1):41.<pub-id pub-id-type="pmid">24252240</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Brodie</surname><given-names>MJ</given-names></name><name><surname>Elder</surname><given-names>AT</given-names></name><name><surname>Kwan</surname><given-names>P</given-names></name></person-group><article-title>Epilepsy in later life</article-title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><issue>11</issue><fpage>1019</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(09)70240-6</pub-id><pub-id pub-id-type="pmid">19800848</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019&#x02013;30.<pub-id pub-id-type="pmid">19800848</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Busch</surname><given-names>RM</given-names></name><name><surname>Najm</surname><given-names>I</given-names></name><name><surname>Hermann</surname><given-names>BP</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name></person-group><article-title>Genetics of cognition in epilepsy</article-title><source>Epilepsy Behav</source><year>2014</year><volume>41</volume><fpage>297</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2014.05.026</pub-id><pub-id pub-id-type="pmid">24973143</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Busch RM, Najm I, Hermann BP, Eng C. Genetics of cognition in epilepsy. Epilepsy Behav. 2014;41:297&#x02013;306.<pub-id pub-id-type="pmid">24973143</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name></person-group><article-title>The association between APOE gene polymorphisms and the risk, characteristics, and prognosis of epilepsy: a systematic review and meta -analysis</article-title><source>Epilepsy Behav</source><year>2024</year><volume>160</volume><fpage>110070</fpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2024.110070</pub-id><pub-id pub-id-type="pmid">39393138</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Liu S. The association between APOE gene polymorphisms and the risk, characteristics, and prognosis of epilepsy: a systematic review and meta -analysis. Epilepsy Behav. 2024;160: 110070.<pub-id pub-id-type="pmid">39393138</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Zawar</surname><given-names>I</given-names></name><name><surname>Kapur</surname><given-names>J</given-names></name><name><surname>Mattos</surname><given-names>MK</given-names></name><name><surname>Aldridge</surname><given-names>CM</given-names></name><name><surname>Manning</surname><given-names>C</given-names></name><name><surname>Quigg</surname><given-names>M</given-names></name></person-group><article-title>Association of seizure control with cognition in people with normal cognition and mild cognitive impairment</article-title><source>Neurology</source><year>2024</year><volume>103</volume><issue>6</issue><fpage>e209820</fpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000209820</pub-id><pub-id pub-id-type="pmid">39173101</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Zawar I, Kapur J, Mattos MK, Aldridge CM, Manning C, Quigg M. Association of seizure control with cognition in people with normal cognition and mild cognitive impairment. Neurology. 2024;103(6): e209820.<pub-id pub-id-type="pmid">39173101</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Scheffer</surname><given-names>IE</given-names></name><name><surname>Berkovic</surname><given-names>S</given-names></name><name><surname>Capovilla</surname><given-names>G</given-names></name><name><surname>Connolly</surname><given-names>MB</given-names></name><name><surname>French</surname><given-names>J</given-names></name><name><surname>Guilhoto</surname><given-names>L</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Mathern</surname><given-names>GW</given-names></name><name><surname>Mosh&#x000e9;</surname><given-names>SL</given-names></name><name><surname>Nordli</surname><given-names>DR</given-names></name><name><surname>Perucca</surname><given-names>E</given-names></name><name><surname>Tomson</surname><given-names>T</given-names></name><name><surname>Wiebe</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y-H</given-names></name><name><surname>Zuberi</surname><given-names>SM</given-names></name></person-group><article-title>ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology</article-title><source>Epilepsia</source><year>2017</year><volume>58</volume><issue>4</issue><fpage>512</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1111/epi.13709</pub-id><pub-id pub-id-type="pmid">28276062</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512&#x02013;21.<pub-id pub-id-type="pmid">28276062</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Batzu</surname><given-names>L</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Geurtsen</surname><given-names>GJ</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Ray Chaudhuri</surname><given-names>K</given-names></name><name><surname>Weintraub</surname><given-names>D</given-names></name></person-group><article-title>Parkinson disease-associated cognitive impairment</article-title><source>Nat Rev Dis Primers</source><year>2021</year><volume>7</volume><issue>1</issue><fpage>47</fpage><pub-id pub-id-type="doi">10.1038/s41572-021-00280-3</pub-id><pub-id pub-id-type="pmid">34210995</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. 2021;7(1):47.<pub-id pub-id-type="pmid">34210995</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Smirnov</surname><given-names>DA</given-names></name><name><surname>Morley</surname><given-names>M</given-names></name><name><surname>Shin</surname><given-names>E</given-names></name><name><surname>Spielman</surname><given-names>RS</given-names></name><name><surname>Cheung</surname><given-names>VG</given-names></name></person-group><article-title>Genetic analysis of radiation-induced changes in human gene expression</article-title><source>Nature</source><year>2009</year><volume>459</volume><issue>7246</issue><fpage>587</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1038/nature07940</pub-id><pub-id pub-id-type="pmid">19349959</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG. Genetic analysis of radiation-induced changes in human gene expression. Nature. 2009;459(7246):587&#x02013;91.<pub-id pub-id-type="pmid">19349959</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Meng</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Mortimer</surname><given-names>JA</given-names></name><name><surname>Borenstein</surname><given-names>AR</given-names></name><name><surname>Hong</surname><given-names>Z</given-names></name></person-group><article-title>Prevalence of mild cognitive impairment in an urban community in China: a cross-sectional analysis of the shanghai aging study</article-title><source>Alzheimer&#x02019;s Dementia</source><year>2015</year><volume>11</volume><issue>3</issue><fpage>300</fpage><pub-id pub-id-type="doi">10.1016/j.jalz.2013.11.002</pub-id><pub-id pub-id-type="pmid">24613707</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Ding D, Zhao Q, Guo Q, Meng H, Wang B, Luo J, et al. Prevalence of mild cognitive impairment in an urban community in China: a cross-sectional analysis of the shanghai aging study. Alzheimer&#x02019;s Dementia. 2015;11(3):300.<pub-id pub-id-type="pmid">24613707</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><article-title>Mini-mental state examination in elderly Chinese: a population-based normative study</article-title><source>JAD</source><year>2016</year><volume>53</volume><issue>2</issue><fpage>487</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.3233/JAD-160119</pub-id><pub-id pub-id-type="pmid">27163822</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Li H, Jia J, Yang Z. Mini-mental state examination in elderly Chinese: a population-based normative study. JAD. 2016;53(2):487&#x02013;96.<pub-id pub-id-type="pmid">27163822</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>D</given-names></name><name><surname>Hong</surname><given-names>Z</given-names></name></person-group><article-title>A Comparison Study of Mild Cognitive Impairment With 3 Memory Tests Among Chinese Individuals</article-title><source>Alzheimer Dis Assoc Disord</source><year>2009</year><volume>23</volume><issue>3</issue><fpage>253</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1097/WAD.0b013e3181999e92</pub-id><pub-id pub-id-type="pmid">19812468</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Guo Q, Zhao Q, Chen M, Ding D, Hong Z. A Comparison Study of Mild Cognitive Impairment With 3 Memory Tests Among Chinese Individuals. Alzheimer Dis Assoc Disord. 2009;23(3):253&#x02013;9.<pub-id pub-id-type="pmid">19812468</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Sekimoto</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Muramatsu</surname><given-names>R</given-names></name><name><surname>Onuma</surname><given-names>T</given-names></name></person-group><article-title>Cognitive dysfunction in drug-na&#x000ef;ve late-onset temporal lobe epilepsy</article-title><source>Epilepsy Behav</source><year>2023</year><volume>146</volume><fpage>109356</fpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2023.109356</pub-id><pub-id pub-id-type="pmid">37499577</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Sekimoto M, Kato M, Muramatsu R, Onuma T. Cognitive dysfunction in drug-na&#x000ef;ve late-onset temporal lobe epilepsy. Epilepsy Behav. 2023;146: 109356.<pub-id pub-id-type="pmid">37499577</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Rawle</surname><given-names>MJ</given-names></name><name><surname>Davis</surname><given-names>D</given-names></name><name><surname>Bendayan</surname><given-names>R</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Kuh</surname><given-names>D</given-names></name><name><surname>Richards</surname><given-names>M</given-names></name></person-group><article-title>Apolipoprotein-E (Apoe) &#x003b5;4 and cognitive decline over the adult life course</article-title><source>Transl Psychiatry</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>18</fpage><pub-id pub-id-type="doi">10.1038/s41398-017-0064-8</pub-id><pub-id pub-id-type="pmid">29317609</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Rawle MJ, Davis D, Bendayan R, Wong A, Kuh D, Richards M. Apolipoprotein-E (Apoe) &#x003b5;4 and cognitive decline over the adult life course. Transl Psychiatry. 2018;8(1):18.<pub-id pub-id-type="pmid">29317609</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Gambardella</surname><given-names>A</given-names></name><name><surname>Aguglia</surname><given-names>U</given-names></name><name><surname>Chifari</surname><given-names>R</given-names></name><name><surname>Labate</surname><given-names>A</given-names></name><name><surname>Manna</surname><given-names>I</given-names></name><name><surname>Serra</surname><given-names>P</given-names></name><name><surname>Romeo</surname><given-names>N</given-names></name><name><surname>Sibilia</surname><given-names>G</given-names></name><name><surname>LePiane</surname><given-names>E</given-names></name><name><surname>Russa</surname><given-names>AL</given-names></name><name><surname>Ventura</surname><given-names>P</given-names></name><name><surname>Cittadella</surname><given-names>R</given-names></name><name><surname>Sasanelli</surname><given-names>F</given-names></name><name><surname>Colosimo</surname><given-names>E</given-names></name><name><surname>Leggio</surname><given-names>U</given-names></name><name><surname>Zappia</surname><given-names>M</given-names></name><name><surname>Quattrone</surname><given-names>A</given-names></name></person-group><article-title>ApoE epsilon4 allele and disease duration affect verbal learning in mild temporal lobe epilepsy</article-title><source>Epilepsia</source><year>2005</year><volume>46</volume><issue>1</issue><fpage>110</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1111/j.0013-9580.2005.15804.x</pub-id><pub-id pub-id-type="pmid">15660776</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Gambardella A, Aguglia U, Chifari R, Labate A, Manna I, Serra P, et al. ApoE epsilon4 allele and disease duration affect verbal learning in mild temporal lobe epilepsy. Epilepsia. 2005;46(1):110&#x02013;7.<pub-id pub-id-type="pmid">15660776</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Thacker</surname><given-names>EL</given-names></name><name><surname>Longstreth</surname><given-names>WT</given-names></name><name><surname>Elkind</surname><given-names>MSV</given-names></name><name><surname>Boehme</surname><given-names>AK</given-names></name></person-group><article-title>Cognitive decline in older adults with epilepsy: the cardiovascular health Study</article-title><source>Epilepsia</source><year>2021</year><volume>62</volume><issue>1</issue><fpage>85</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1111/epi.16748</pub-id><pub-id pub-id-type="pmid">33227164</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Choi H, Thacker EL, Longstreth WT, Elkind MSV, Boehme AK. Cognitive decline in older adults with epilepsy: the cardiovascular health Study. Epilepsia. 2021;62(1):85&#x02013;97.<pub-id pub-id-type="pmid">33227164</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Doherty</surname><given-names>C</given-names></name><name><surname>Kinzy</surname><given-names>TG</given-names></name><name><surname>Ferguson</surname><given-names>L</given-names></name><name><surname>Altemus</surname><given-names>J</given-names></name><name><surname>Hermann</surname><given-names>BP</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Najm</surname><given-names>I</given-names></name><name><surname>Busch</surname><given-names>RM</given-names></name></person-group><article-title>The role of genetic polymorphisms in executive functioning performance in temporal lobe epilepsy</article-title><source>Epilepsy Behav</source><year>2021</year><volume>121</volume><fpage>108088</fpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2021.108088</pub-id><pub-id pub-id-type="pmid">34102472</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Doherty C, Kinzy TG, Ferguson L, Altemus J, Hermann BP, Eng C, et al. The role of genetic polymorphisms in executive functioning performance in temporal lobe epilepsy. Epilepsy Behav. 2021;121:108088.<pub-id pub-id-type="pmid">34102472</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Cognitive impairment as a comorbidity of epilepsy in older adults: analysis of global and domain-specific cognition</article-title><source>Epileptic Disord</source><year>2023</year><volume>25</volume><issue>1</issue><fpage>65</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1002/epd2.20057</pub-id><pub-id pub-id-type="pmid">37013261</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Chai X, Xiao Z, Zhao Q, Wang J, Ding D, Zhang J. Cognitive impairment as a comorbidity of epilepsy in older adults: analysis of global and domain-specific cognition. Epileptic Disord. 2023;25(1):65&#x02013;73.<pub-id pub-id-type="pmid">37013261</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name></person-group><article-title>Association of apolipoprotein E genotypes with epilepsy risk: a systematic review and meta-analysis</article-title><source>Epilepsy Behav</source><year>2019</year><volume>98</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2019.06.015</pub-id><pub-id pub-id-type="pmid">31299529</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Liang Y, Zhou Z, Wang H, Cheng X, Zhong S, Zhao C. Association of apolipoprotein E genotypes with epilepsy risk: a systematic review and meta-analysis. Epilepsy Behav. 2019;98:27&#x02013;35.<pub-id pub-id-type="pmid">31299529</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>LM</given-names></name><name><surname>Allan</surname><given-names>SM</given-names></name><name><surname>Parkes</surname><given-names>LM</given-names></name><name><surname>Emsley</surname><given-names>HCA</given-names></name></person-group><article-title>Occult cerebrovascular disease and late-onset epilepsy: could loss of neurovascular unit integrity be a viable model?</article-title><source>Cardiovasc Psychiatry Neurol</source><year>2011</year><volume>2011</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1155/2011/130406</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Gibson LM, Allan SM, Parkes LM, Emsley HCA. Occult cerebrovascular disease and late-onset epilepsy: could loss of neurovascular unit integrity be a viable model? Cardiovasc Psychiatry Neurol. 2011;2011:1&#x02013;7.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>van Vliet</surname><given-names>EA</given-names></name><name><surname>Marchi</surname><given-names>N</given-names></name></person-group><article-title>Neurovascular unit dysfunction as a mechanism of seizures and epilepsy during aging</article-title><source>Epilepsia</source><year>2022</year><volume>63</volume><issue>6</issue><fpage>1297</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1111/epi.17210</pub-id><pub-id pub-id-type="pmid">35218208</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">van Vliet EA, Marchi N. Neurovascular unit dysfunction as a mechanism of seizures and epilepsy during aging. Epilepsia. 2022;63(6):1297&#x02013;313.<pub-id pub-id-type="pmid">35218208</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Montagne</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>SR</given-names></name><name><surname>Sweeney</surname><given-names>MD</given-names></name><name><surname>Halliday</surname><given-names>MR</given-names></name><name><surname>Sagare</surname><given-names>AP</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Toga</surname><given-names>AW</given-names></name><name><surname>Jacobs</surname><given-names>RE</given-names></name><name><surname>Liu</surname><given-names>CY</given-names></name><name><surname>Amezcua</surname><given-names>L</given-names></name><name><surname>Harrington</surname><given-names>MG</given-names></name><name><surname>Chui</surname><given-names>HC</given-names></name><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group><article-title>Blood-Brain Barrier Breakdown in the Aging Human Hippocampus</article-title><source>Neuron</source><year>2015</year><volume>85</volume><issue>2</issue><fpage>296</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.12.032</pub-id><pub-id pub-id-type="pmid">25611508</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, et al. Blood-Brain Barrier Breakdown in the Aging Human Hippocampus. Neuron. 2015;85(2):296&#x02013;302.<pub-id pub-id-type="pmid">25611508</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Kerkhofs</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>E</given-names></name><name><surname>Uiterwijk</surname><given-names>R</given-names></name><name><surname>Hoff</surname><given-names>EI</given-names></name><name><surname>Jansen</surname><given-names>JFA</given-names></name><name><surname>Staals</surname><given-names>J</given-names></name><name><surname>Backes</surname><given-names>WH</given-names></name><name><surname>van Oostenbrugge</surname><given-names>RJ</given-names></name></person-group><article-title>Blood&#x02013;brain barrier leakage at baseline and cognitive decline in cerebral small vessel disease: a 2-year follow-up study</article-title><source>GeroScience</source><year>2021</year><volume>43</volume><issue>4</issue><fpage>1643</fpage><lpage>1652</lpage><pub-id pub-id-type="doi">10.1007/s11357-021-00399-x</pub-id><pub-id pub-id-type="pmid">34160780</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Kerkhofs D, Wong SM, Zhang E, Uiterwijk R, Hoff EI, Jansen JFA, et al. Blood&#x02013;brain barrier leakage at baseline and cognitive decline in cerebral small vessel disease: a 2-year follow-up study. GeroScience. 2021;43(4):1643&#x02013;52.<pub-id pub-id-type="pmid">34160780</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Nation</surname><given-names>DA</given-names></name><name><surname>Sweeney</surname><given-names>MD</given-names></name><name><surname>Montagne</surname><given-names>A</given-names></name><name><surname>Sagare</surname><given-names>AP</given-names></name><name><surname>D&#x02019;Orazio</surname><given-names>LM</given-names></name><name><surname>Pachicano</surname><given-names>M</given-names></name><name><surname>Sepehrband</surname><given-names>F</given-names></name><name><surname>Nelson</surname><given-names>AR</given-names></name><name><surname>Buennagel</surname><given-names>DP</given-names></name><name><surname>Harrington</surname><given-names>MG</given-names></name><name><surname>Benzinger</surname><given-names>TLS</given-names></name><name><surname>Fagan</surname><given-names>AM</given-names></name><name><surname>Ringman</surname><given-names>JM</given-names></name><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Chui</surname><given-names>HC</given-names></name><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Toga</surname><given-names>AW</given-names></name><name><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group><article-title>Blood&#x02013;brain barrier breakdown is an early biomarker of human cognitive dysfunction</article-title><source>Nat Med</source><year>2019</year><volume>25</volume><issue>2</issue><fpage>270</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0297-y</pub-id><pub-id pub-id-type="pmid">30643288</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Nation DA, Sweeney MD, Montagne A, Sagare AP, D&#x02019;Orazio LM, Pachicano M, et al. Blood&#x02013;brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25(2):270&#x02013;6.<pub-id pub-id-type="pmid">30643288</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Helmstaedter</surname><given-names>C</given-names></name><name><surname>Kurthen</surname><given-names>M</given-names></name><name><surname>Lux</surname><given-names>S</given-names></name><name><surname>Reuber</surname><given-names>M</given-names></name><name><surname>Elger</surname><given-names>CE</given-names></name></person-group><article-title>Chronic epilepsy and cognition: A longitudinal study in temporal lobe epilepsy</article-title><source>Ann Neurol</source><year>2003</year><volume>54</volume><issue>4</issue><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1002/ana.10692</pub-id><pub-id pub-id-type="pmid">14520652</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Helmstaedter C, Kurthen M, Lux S, Reuber M, Elger CE. Chronic epilepsy and cognition: A longitudinal study in temporal lobe epilepsy. Ann Neurol. 2003;54(4):425&#x02013;32.<pub-id pub-id-type="pmid">14520652</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Kleen</surname><given-names>JK</given-names></name><name><surname>Scott</surname><given-names>RC</given-names></name><name><surname>Holmes</surname><given-names>GL</given-names></name><name><surname>Roberts</surname><given-names>DW</given-names></name><name><surname>Rundle</surname><given-names>MM</given-names></name><name><surname>Testorf</surname><given-names>M</given-names></name><name><surname>Lenck-Santini</surname><given-names>P-P</given-names></name><name><surname>Jobst</surname><given-names>BC</given-names></name></person-group><article-title>Hippocampal interictal epileptiform activity disrupts cognition in humans</article-title><source>Neurology</source><year>2013</year><volume>81</volume><issue>1</issue><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e318297ee50</pub-id><pub-id pub-id-type="pmid">23685931</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Kleen JK, Scott RC, Holmes GL, Roberts DW, Rundle MM, Testorf M, et al. Hippocampal interictal epileptiform activity disrupts cognition in humans. Neurology. 2013;81(1):18&#x02013;24.<pub-id pub-id-type="pmid">23685931</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Vossel</surname><given-names>K</given-names></name><name><surname>Ranasinghe</surname><given-names>KG</given-names></name><name><surname>Beagle</surname><given-names>AJ</given-names></name><name><surname>La</surname><given-names>A</given-names></name><name><surname>Ah Pook</surname><given-names>K</given-names></name><name><surname>Castro</surname><given-names>M</given-names></name><name><surname>Mizuiri</surname><given-names>D</given-names></name><name><surname>Honma</surname><given-names>SM</given-names></name><name><surname>Venkateswaran</surname><given-names>N</given-names></name><name><surname>Koestler</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name><name><surname>Howell</surname><given-names>MJ</given-names></name><name><surname>Possin</surname><given-names>KL</given-names></name><name><surname>Kramer</surname><given-names>JH</given-names></name><name><surname>Boxer</surname><given-names>AL</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Nagarajan</surname><given-names>SS</given-names></name><name><surname>Kirsch</surname><given-names>HE</given-names></name></person-group><article-title>Effect of levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial</article-title><source>JAMA Neurol</source><year>2021</year><volume>78</volume><issue>11</issue><fpage>1345</fpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2021.3310</pub-id><pub-id pub-id-type="pmid">34570177</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, et al. Effect of levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial. JAMA Neurol. 2021;78(11):1345.<pub-id pub-id-type="pmid">34570177</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>